drug · antibody
patient view →blinatumomab
Marketedupdated 2mo agoby $AMGN AMGEN INC🔗 ChEMBL
Approvedcommunity read0 votes
Antibody drug with a maximum clinical stage of Approval (across all indications), with 4 approved and 12 investigational indications.
targets
B-lymphocyte antigen CD19T cell surface glycoprotein CD3
all catalysts(25)
approval · 23
phase 1 2 completion · 1
phase 2 completion · 1
News(0)
no news has mentioned this drug yet
comments(0)
5-min edit window · permanent after that